Brian M. Culley - 10 Mar 2022 Form 4 Insider Report for Lineage Cell Therapeutics, Inc. (LCTX)

Role
President and CEO, Director
Signature
/s/ Brian M. Culley
Issuer symbol
LCTX
Transactions as of
10 Mar 2022
Net transactions value
$0
Form type
4
Filing time
11 Mar 2022, 19:45:59 UTC
Previous filing
15 Feb 2022
Next filing
28 Mar 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LCTX Employee Stock Option (Right to Buy) Award $0 +1,250,000 $0.000000 1,250,000 10 Mar 2022 Common Shares 1,250,000 $1.40 Direct F1
transaction LCTX Restricted Stock Units Award $0 +300,000 $0.000000 300,000 10 Mar 2022 Common Shares 300,000 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 One quarter of the options shall vest on March 10, 2023, and the balance shall vest in 36 monthly installments thereafter upon the completion of each month of continuous employment.
F2 Grant of restricted stock units under Lineage's 2021 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one Common Share.
F3 One-third of the shares will vest on or prior to March 9, 2023, and the second and third anniversaries of such date, upon the achievement of certain per share performance targets, calculated based on the trailing 20 trading day volume weighted average price of the Company's common stock as of the date of determination.